English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Plus monthly

Global: Zendy Tools annual

Global: Zendy Tools monthly

Global: Zendy Free Plan

We investigate the impact of pharmaceutical spending and retail sales in major anatomical therapeutic classes on domestic early-stage innovation. For our analysis, we incorporate panel data from 1999 to 2019 from countries of the European Union. The econometric analysis uses fixed effects with instrumental variable estimation to address potential endogeneity of pharmaceutical spending. The analysis is based on two instruments, social insurance coverage for pharmaceutical products and government defence expenditures, and controls for pharmaceutical R&amp;D spending by U.S.-owned firms and other potential confounders. Two-stage least squares (2SLS) estimates show that a 1% increase in pharmaceutical spending per capita increases patent applications by 2.2%. We find similar results when sales in each therapeutic class are designated as the independent variable. Results are robust when using different time lags and patent grants as a measure of innovation. Overall, increasing pharmaceutical spending in countries of the European Union increases domestic early-stage innovation.

Pharmaceutical spending and early-stage innovation in EU countries